More than half of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to a study in Italy. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of…

Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…

Many people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) experience substantial “hidden disabilities,” such as depression or fatigue, a study highlights. Findings indicate that treatment with disease-modifying therapies generally does not affect the severity of these problems, at least in the short term. “Considering the substantial impact that hidden…

Eating a ketogenic diet — one low in carbohydrates and high in fats — led to markedly less fatigue and depression for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial that was designed to assess the tolerability of the dietary intervention. Measures of disability and quality…

Kesimpta (ofatumumab) is now accessible to eligible Canadians with relapsing-remitting multiple sclerosis (RRMS) through public drug plans in Ontario and Quebec. The treatment has been included as an exceptional medication under both the Ontario Drug Benefit Exceptional Access Program and the Régie de l’assurance maladie du Québec. This…

Treatment with Gilenya (fingolimod) for up to four years was found safe and lowered relapse rates among people with multiple sclerosis (MS) in the Czech Republic, according to a real-world study called GOLEMS. Older age, lower disability level, and fewer relapses prior to the treatment’s start were all…

Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings — supporting evobrutinib’s therapeutic potential in relapsing MS — were shared in an…

Six weeks of aerobic exercise led to benefits in cognition, fatigue, and depression among people with relapsing-remitting multiple sclerosis (RRMS), which may be due to increases in blood levels of a hormone called irisin, according to data from a randomized, controlled trial. “Considering the high prevalence of neuropsychiatric symptoms…

COVID-19 does not seem to be linked to increased disability worsening or more relapses in the long term for people with relapsing-remitting multiple sclerosis (RRMS), an Iranian study suggests. The study was relatively small, the researchers noted, indicating that more research is needed in the future to determine the…

Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, “…

Reviewing an MRI of one’s brain and seeing lesions on it is a frightening prospect for people with multiple sclerosis (MS). “The lesions, the bright spots on a brain scan, that’s probably the last place in your body most of us want to see things. [It’s] such an important…

A risk variant in the BDNF gene is tied to increased brain inflammation and reduced cortical thickness on MRI scans in people newly diagnosed with relapsing-remitting multiple sclerosis (RRMS), a recent study found. “We report for the first time an association between the BDNF [genetic variant] and central inflammation…

Among healthcare providers in the U.K., considerable variation exists in marking the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), a study based on interview responses reports. Neurologists and nurses with MS specialties also expressed a reluctance to label patients as having progressed to…

Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) — an immunization often given to infants and small children in countries where TB is common — does not decrease a person’s risk of developing multiple sclerosis (MS), according to a new study. “Within a large birth cohort…

Initial treatment with Novantrone (mitoxantrone) can reduce the risk of relapses and worsening disability in people with highly active relapsing-remitting multiple sclerosis (RRMS), according to a 10-year study from France. “Our results support the short-term use of [Novantrone], followed by a maintenance therapy for patients with early highly…

A substantial amount of disability worsening happens independently of relapses in people with multiple sclerosis (MS), including those in earlier stages of relapsing-remitting disease, a study in a large patient database reported. While its findings “confirm relapses contribute to the accumulation of disability, primarily early in multiple sclerosis,” data…

“Most of the time, the greatest rewards come from doing the things that scare you the most. Maybe you’ll get everything you wish for. Maybe you’ll get more than you ever could have imagined. Who knows where life will take you? The road is long, and in the end, the…

A short-term ketogenic diet, which dramatically cuts carbohydrate consumption, is safe and results in significant improvements in people with relapsing-remitting multiple sclerosis (RRMS), a small study in patients reported. “Our study provides evidence that a ketogenic diet is safe and beneficial, reducing some symptoms for people with MS, when…

Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…

A higher burden of lesions in the brain’s cortex is associated with a greater likelihood of disability worsening in multiple sclerosis (MS) and transition to secondary progressive MS (SPMS), researchers report. These results suggest that “monitoring cortical lesion volume … could be useful when stratifying risk of disability…

A faster rate of atrophy in the spinal cord of people in earlier stages of multiple sclerosis (MS) is likely to indicate “silent progression” — worsening disability in the absence of relapses — and a swifter conversion to secondary progressive MS (SPMS), new data show. Antje Bischof, MD, with…

Iron rim lesions, or specific regions of chronic inflammation seen on MRI scans of the brain, are associated with greater disability and poorer outcomes in multiple sclerosis (MS), a study indicates. These findings “could support the use of iron rim lesions as an imaging biomarker for disease severity and…

Sports was a huge part of Armand Thoinet’s life, and when he was diagnosed with relapsing-remitting multiple sclerosis (MS) one week before his 19th birthday, that life turned upside down. He could no longer engage in activities that mattered greatly to him, such as rugby, tennis, and skiing. “I…

Multiple sclerosis (MS) is characterized by changes in methylation — a type of chemical modification in the DNA that changes how genes are read — in immune cells called T-cells, according to a new study. The results also suggest that treatments for MS can help to normalize methylation…

Women with relapsing-remitting multiple sclerosis (RRMS) have more brain lesions and accelerated brain volume loss (BVL) after pregnancy compared with pre-pregnancy measurements, recent data showed. Brain lesions in the early postpartum period — the first months following childbirth — were associated with a higher risk of worsened disability and relapse…

Acthar Gel (repository corticotropin injection) may be useful for managing disease relapses in people with relapsing-remitting multiple sclerosis (RRMS) who fail to respond to treatment with corticosteroids, according to results from a small clinical trial. The study, “Results from a multicenter, randomized, double-blind, placebo-controlled study…

People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around their brain and spinal cord, a study found. “This work not only furthers our understanding of the role of gut-brain communication in neurodegenerative disease progression, but also provides a potential…

Visual disturbances are common in people with multiple sclerosis (MS), particularly among those with secondary progressive MS (SPMS), longer disease duration, and worse disability status, a new study has found. Yet, “visual complaints may occur in people with all types of MS, anytime along the disease course, and…

An imaging technique called optical coherence tomography (OCT) could be useful for monitoring nervous system damage in people with multiple sclerosis (MS), especially early on in the disease, a study in patients reports. The study, “Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study,”…

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…